Forteo vs Teribone

Searching study for comparative examination in Forteo and Teribone in an osteoporosis patient after menopause

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080225043

Enrollment

100

Registered

2020-01-29

Start date

2020-04-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

investigational material(s) Generic name etc : Forteo INN of investigational material : teriparatide Therapeutic category code : --- Other Dosage and Administration for Investigational material : Subc

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)Osteoporosis patient after menopause,who comes under more than the following one of 1 items 1.Bone density; -2.5SD or less and Vulnerable fracture 2.Lumbar spine bone density;Less than -3.3SD 3.Existing vertebral fracture;More than 2 4.Semi-quantitative evaluation method results(Existing vertebral fracture) is Grade3 5.fracture of femur in the past 3)The patient by whom own injection is possible

Exclusion criteria

Exclusion criteria: 1)Hypercalcemia 2)Risk of osteosarcoma occurrence is high 3)Primary malignant bone tumor or Metastatic bone tumor 4)Metabolic bone disease without osteoporosis 5)Hypersensitivity for teriparatide 6)A doctor in attendance is the patient who judged that participation in this research was unsuitable

Design outcomes

Primary

Measure	Time frame
efficacy adherence, Safety after 24 months	—

Secondary

Measure	Time frame
efficacy Bone density variation after 3,6,12,18,24 months efficacy P1NP,TRACP-5b after 3,6,12,18,24 months efficacy X-ray examination,Homocysteine,AGE after 12,24 months	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026